Tests tesamorelin with exercise to improve physical function in people with HIV
Tests tesamorelin plus home exercise in adults aged 50 to 80 with HIV.
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Aurora and Boston, United StatesSee the 2 sites
- Trial code
- Registry title
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 10 Jul 2025
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tesamorelin
- Placebo
- Exercise
- Record updated
- 19 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50-80 living with HIV who do little exercise. It tests whether tesamorelin plus home exercise improves physical function.
- Age
- 50 to 80 years old
- Sex
- Men and women
- Disease stage
- HIV on antiretroviral therapy for at least 1 year, with HIV-1 RNA <200 copies/mL and CD4+ T cell count >200/µL. At least 1 Fried frailty criterion and extra belly fat by waist measures.
- Earlier treatment
- Must have taken antiretroviral therapy for at least 1 year. Cannot have used tesamorelin or other growth hormone-based therapy within 6 months.
- Biomarker or test result
- IGF-1 z-score must not be above 2.0. HbA1c must not be above 8% (64 mmol/mol). Women need AMH <20 pg/mL unless both ovaries were removed.
Main reasons for not taking part
- Cancer within 24 months (except non-melanoma skin cancer)
- Unstable heart disease, chest pain suspicious for angina, or serious arrhythmia
- History of hypopituitarism, head irradiation, or other conditions affecting the GH/IGF-1 axis
- Allergy to tesamorelin or mannitol
- Recent change in testosterone, corticosteroid or glucose-lowering medication within 3 months
This trial only enrols participants living with HIV. The registry sentence this rests on: Documented HIV infection on suppressive antiretroviral therapy for at least 1 year with HIV-1 RNA <200 copies/mL and CD4+ T cell count >200/µL 3
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Men and women, 50-80 years old
- Documented HIV infection on suppressive antiretroviral therapy for at least 1 year with HIV-1 RNA <200 copies/mL and CD4+ T cell count >200/µL 3
- Sedentary lifestyle, defined as self-reported physical activity that breaks a sweat <3 days/week with no regular resistance exercise in the past 3 months
- ≥1 Fried frailty criterion (weakness, slow gait speed, exhaustion, decreased physical activity, or unintentional weight loss as defined by specific thresholds)
- Excess abdominal adiposity as indicated by at least one of the following elevated anthropometric measures assessed at Screen: (1) waist circumference ≥102 cm in non-Asian males (≥90 cm in Asian males) or ≥88 cm in non-Asian females (≥80 cm in Asian females); (2) waist-to-hip ratio ≥0.9 in males or ≥0.85 in females; (3) waist-to-height ratio ≥0.5 in males and females
- Normal mammogram within 2 years (females ≤74 years old) or prostate specific antigen <4 ng/mL (males ≤70 years old) per U.S. Preventive Services Task Force (USPSTF) age-appropriate cancer screening guidelines
- For females, postmenopausal defined as no menses for ≥12 months and anti-müllerian hormone (AMH) <20 pg/mL or history of bilateral oophorectomy at least 3 months ago
- Provider approval to participate
Who cannot take part
- Use of tesamorelin or other growth hormone (GH)-based therapy within 6 months
- Supraphysiologic testosterone or corticosteroid exposure, or change in exogenous testosterone or corticosteroid dose within 3 months
- Active or suspected malignancy (with the exception of non-melanoma skin cancer) within 24 months
- Active or unstable coronary artery disease, chest pain suspicious for angina, or serious arrythmia
- History of hypopituitarism, head irradiation, or other conditions known to affect the GH/IGF-1 axis
- Known hypersensitivity to tesamorelin or mannitol
- Acute or chronic illness judged by the investigator to represent a contraindication to study participation
- HbA1c >8%
- Change in glucose-lowering medication (e.g., glucagon-like peptide-1 receptor agonists) within 3 months
- Insulin-like growth factor 1 (IGF-1) z-score >2.0
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Where in United States
- University of Colorado Anschutz Medical CampusAurora, United StatesContact: Kristine M. Erlandson, MDTaking people
- Massachusetts General HospitalBoston, United StatesContact: Lindsay T Fourman, MDTaking people
About the trial
What the trial wants to find out
People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long-term.
Read full original descriptionShow less
The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise. Tesamorelin is a growth hormone-releasing hormone analogue that is FDA-approved to treat abdominal fat accumulation in people with HIV. While tesamorelin has also been shown to increase muscle mass and improve measures of muscle health, its effects on physical performance and muscle strength have not yet been evaluated.
During a 24-week intervention phase, half of participants will be randomly assigned to receive tesamorelin and half of participants will be randomly assigned to receive placebo (a look-alike substance that contains no drug). All participants also will engage in a home-based exercise intervention supervised by an exercise coach. During a subsequent 24-week extension phase, individuals will be monitored off study drug and supervised exercise, and be encouraged to continue to exercise independently.
The investigators will investigate effects of tesamorelin on physical function, muscle mass and quality, quality of life, and exercise adherence and self-efficacy. They also will evaluate whether effects of tesamorelin are maintained following treatment cessation. This study may identify an important strategy to improve how individuals aging with HIV function and feel with potential applications to other patient populations.
The 2 groups in the trial
- Tesamorelin Plus ExerciseExisting treatment, for comparison
Tesamorelin WR 1.28 mg given subcutaneously daily plus home-based semi-supervised exercise intervention
Treatment: Tesamorelin and Exercise
- Placebo Plus ExercisePlacebo, for comparison
Identical placebo given subcutaneously daily plus home-based semi-supervised exercise intervention
Treatment: Placebo and Exercise
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
- Plain-language title
- Tests tesamorelin with exercise to improve physical function in people with HIVGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06554717, who can take part
- Publications
- Record updated
- 19 May 2026